<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03057756</url>
  </required_header>
  <id_info>
    <org_study_id>TB-MR 001/2015</org_study_id>
    <nct_id>NCT03057756</nct_id>
  </id_info>
  <brief_title>Treatment of Tuberculosis Multidrug Resistance Treatment of Tuberculosis Multidrug Resistance</brief_title>
  <acronym>TB-MR</acronym>
  <official_title>Nine Months' Short Course Regimen Protocol for the Treatment of Multidrug Resistance-tuberculosis (MDR-TB) Patients in Gabon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de Recherche Médicale de Lambaréné</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Tropical Medicine, University of Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre de Recherche Médicale de Lambaréné</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal objective is to evaluate a cure rate and number of adverse events of with
      confirmed multidrug-resistant tuberculosis patient treated with a 9months regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study participants will be followed up, under existing protocol derived from a study protocol
      developed by the &quot;Union internationale contre les maladies respiratoires&quot; and carried out
      already in 9 Africans countries. Participants will be hospitalised for at least four month,
      period which they will be given treatments, assessed for adverse events, monitored for TB-MR
      strains using culture techniques, at the monthly basis. If patients found with negative
      sputum culture at month four they will be dischrged from the hospital, and then treated four
      an additional five montns and then follow up, clinically and biologically for an additional
      six months before being declared as cured.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2015</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 4, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>15 Months</target_duration>
  <primary_outcome>
    <measure>cure rate post treatment</measure>
    <time_frame>Six months post treatment</time_frame>
    <description>Proportion of participants alive and presented with negative sputum culture for TB and with the absence of clinical, X-Ray and biological disorders related to TB</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TB-culture</measure>
    <time_frame>4 months after start of the treatment</time_frame>
    <description>First TB culture negative time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regimen tolorability</measure>
    <time_frame>Throughout treatment period (9months)</time_frame>
    <description>treatment, safety through clinical and biological assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>duration of participant in the study (15months)</time_frame>
    <description>solicited and unsolicited adverse events</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multi-drug Resistant Tuberculosis</condition>
  <arm_group>
    <arm_group_label>TB-MR patients</arm_group_label>
    <description>Patients older than 15 years old receiving Km+ Mfx+ Pto + H + Cfz +E+Z</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Km+ Mfx+ Pto + H + Cfz +E+Z</intervention_name>
    <description>Second generation of anti tuberculosis Kanamycine, Moxifloxacine,Prothionamide, isoniazide,Clofazimine, Ethambutol,Pyrazinamide</description>
    <arm_group_label>TB-MR patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        study population will consist of all consecutive patients with bacteriologically proven
        MDR-TB who fulfil the inclusion criteria .
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Aged 15 years and above

          -  Never been treated with second line anti-TB drugs for more than one month,

          -  Give written consent to participate

          -  Agree to be hospitalised for at least four months in specialised healthcare

          -  Willing to adhere to ambulatory directly observed treatment by a healthcare worker;

        Exclusion criteria:

          -  Pregnant during inclusion process

          -  Presented with altered clinical status condition as judged by the clinician

          -  Knowing of history of hypersensitivity reaction to any of the drugs to be used

          -  Baseline ECG does not show a QT space superior to 500ms

          -  Refusal to participate into study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayola A Adegnika, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Recherches Médicales de Lambaréné</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ayola A Adegnika, MD, PhD</last_name>
    <phone>+24107406464</phone>
    <email>aadegnika@cermel.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ronald J Edoa, MD</last_name>
    <phone>+24107448620</phone>
    <email>j.ronaldedoa@cermel.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de Recherches Médicales de Lambaréné</name>
      <address>
        <city>Lambarene</city>
        <state>Please Select</state>
        <zip>BP 242</zip>
        <country>Gabon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayola A Adegnika, PhD, MD</last_name>
      <phone>+24107406464</phone>
      <email>aadegnika@cermel.org</email>
    </contact>
    <contact_backup>
      <last_name>Ronald J EDOA, MD</last_name>
      <email>j.ronaldedoa@cermel.org</email>
    </contact_backup>
    <investigator>
      <last_name>Martin P Grobusch, PhD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susie Goulds, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bertrand O Lell, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marguérite Massinga Loembe, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulysse Ateba Ngoa, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Gabon</country>
  </location_countries>
  <link>
    <url>http://apps.who.int//iris/handle/10665/66368</url>
    <description>web based information</description>
  </link>
  <results_reference>
    <citation>Eurosurveillance editorial team. WHO revised definitions and reporting framework for tuberculosis. Euro Surveill. 2013 Apr 18;18(16):20455.</citation>
    <PMID>23611033</PMID>
  </results_reference>
  <results_reference>
    <citation>Pablos-Méndez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, Cohn DL, Lambregts-van Weezenbeek CS, Kim SJ, Chaulet P, Nunn P. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med. 1998 Jun 4;338(23):1641-9. Erratum in: N England J Med 1998 Jul 9;339(2):139.</citation>
    <PMID>9614254</PMID>
  </results_reference>
  <results_reference>
    <citation>Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH, Keravec J, Keshavjee S, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev A, Migliori GB, Mirzayev F, Mitnick CD, Nunn P, Nwagboniwe G, Oxlade O, Palmero D, Pavlinac P, Quelapio MI, Raviglione MC, Rich ML, Royce S, Rüsch-Gerdes S, Salakaia A, Sarin R, Sculier D, Varaine F, Vitoria M, Walson JL, Wares F, Weyer K, White RA, Zignol M. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011 Sep;38(3):516-28. doi: 10.1183/09031936.00073611. Epub 2011 Aug 4.</citation>
    <PMID>21828024</PMID>
  </results_reference>
  <results_reference>
    <citation>Stolp SM, Huson MA, Janssen S, Beyeme JO, Grobusch MP. Tuberculosis patients hospitalized in the Albert Schweitzer Hospital, Lambaréné, Gabon-a retrospective observational study. Clin Microbiol Infect. 2013 Nov;19(11):E499-501. doi: 10.1111/1469-0691.12278. Epub 2013 Jul 4.</citation>
    <PMID>23826878</PMID>
  </results_reference>
  <results_reference>
    <citation>Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010 Sep 1;182(5):684-92. doi: 10.1164/rccm.201001-0077OC. Epub 2010 May 4.</citation>
    <PMID>20442432</PMID>
  </results_reference>
  <results_reference>
    <citation>Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, Zarovska E, Rich ML, Fraser HS, Alarcón E, Cegielski JP, Grzemska M, Gupta R, Espinal M. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005 Jun;9(6):640-5.</citation>
    <PMID>15971391</PMID>
  </results_reference>
  <results_reference>
    <citation>Chiang CY, Caminero JA, Enarson DA. Reporting on multidrug-resistant tuberculosis: a proposed definition for the treatment outcome 'failed'. Int J Tuberc Lung Dis. 2009 May;13(5):548-50. Review.</citation>
    <PMID>19383184</PMID>
  </results_reference>
  <results_reference>
    <citation>World Health Organization; International Union Against Tuberculosis and Lung Disease; Royal Netherlands Tuberculosis Association. Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis. 2001 Mar;5(3):213-5.</citation>
    <PMID>11326818</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2017</study_first_submitted>
  <study_first_submitted_qc>February 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2017</study_first_posted>
  <last_update_submitted>February 17, 2017</last_update_submitted>
  <last_update_submitted_qc>February 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre de Recherche Médicale de Lambaréné</investigator_affiliation>
    <investigator_full_name>Ayola Akim Adegnika, MD, MSc, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Multi-drug Resistant Tuberculosis</keyword>
  <keyword>short course regimen protocol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

